Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-B
- 1 September 2005
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 98 (3) , 467-483
- https://doi.org/10.1016/j.ygyno.2005.05.003
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancersBritish Journal of Cancer, 2004
- Lymphatics at the crossroads of angiogenesis and lymphangiogenesisJournal of Anatomy, 2004
- Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancerGynecologic Oncology, 2003
- Expression of vascular endothelial growth factor (VEGF)‐C and VEGF‐D, and their receptor VEGFR‐3, during different stages of cervical carcinogenesisThe Journal of Pathology, 2003
- Insulin‐like Growth Factor II in Gynecological Cancers: A Preliminary StudyAmerican Journal of Reproductive Immunology, 2003
- A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancerBritish Journal of Cancer, 2002
- Circulating VEGF Levels in the Serum of Gastric Cancer PatientsAnnals of Surgery, 2002
- Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survivalCancer Letters, 2002
- Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors*Medical and Pediatric Oncology, 2001
- Cervical Epidermal Growth Factor‐Receptor (EGF‐R) and Serum Insulin‐Like Growth Factor II (IGF‐II) Levels are Potential Markers for Cervical Cancer1American Journal of Reproductive Immunology, 2000